Security Snapshot

RHYTHM PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (RYTM) Institutional Ownership

CUSIP: 76243J105

13F Institutional Holders and Ownership History from Q4 2017 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

305

Shares (Excl. Options)

77.23MFull value: 77,229,617 · shares · 30 Jun 2026

Price

$111.03

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+3,702,073
Value change
+$437,344,841
Number of holders
305
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
69,875,824
SEC-reported price per share
$90.77
Insider filing price
$90.77
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • RYTM - RHYTHM PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share is tracked under CUSIP 76243J105.
  • 305 institutions reported positions in Q2 2026.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 284 to 305 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $6.39BFull value: $6,388,316,182 · USD · 31 Mar 2026
    to
    $8.55BFull value: $8,550,536,847 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 305 institutions filings for Q2 2026.

Open SEC evidence

Security key

76243J105

13F reference period

Q2 2026

13F holders

305

13D/G owners

8

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
8
Security
RYTM
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% +13% $662,816,935 +$109,906,623 6,666,837 +20% RA Capital Management, L.P. 31 Dec 2025
BAKER BROS. ADVISORS LP 8.9% $360,984,750 5,604,483 Baker Bros. Advisors LP 31 Mar 2025
BlackRock, Inc. 6.9% $281,130,327 4,364,700 BlackRock, Inc. 31 Mar 2025
JPMORGAN CHASE & CO 5.1% $339,314,910 3,563,667 JPMORGAN CHASE & CO. 30 Sep 2026
PERCEPTIVE ADVISORS LLC 5.1% -24% $303,708,528 -$77,990,196 3,519,626 -20% Perceptive Advisors LLC 31 Mar 2026
PRIMECAP MANAGEMENT CO/CA/ 5.2% -20% $345,849,272 -$77,964,170 3,478,669 -18% PRIMECAP MANAGEMENT CO/CA/ 31 Dec 2025
VANGUARD CAPITAL MANAGEMENT LLC 5% $298,563,575 3,432,949 Vanguard Capital Management 31 Mar 2026
GOLDMAN SACHS GROUP INC 3% $117,157,406 1,818,932 THE GOLDMAN SACHS GROUP, INC. 31 Dec 2024
As of 30 Jun 2026, 305 institutional investors reported holding
77.23MFull value: 77,229,617 · shares · 30 Jun 2026
shares of RHYTHM PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (RYTM). This represents 111% of the company’s total
69.88MFull value: 69,875,824 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
83%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 9.5% 6,666,837 0% 6.4% $740,218,912
BlackRock, Inc. 8.8% 6,156,902 -1.3% 0.01% $683,600,828
BAKER BROS. ADVISORS LP 8% 5,604,483 0% 3.1% $622,265,747
PRIMECAP MANAGEMENT CO/CA/ 4.5% 3,168,853 -7.3% 0.21% $351,837,748
VANGUARD PORTFOLIO MANAGEMENT LLC 4.5% 3,136,895 +3.2% 0.02% $348,289,452
VANGUARD CAPITAL MANAGEMENT LLC 4.3% 3,005,977 +1.3% 0.01% $333,753,626
JPMORGAN CHASE & CO 3.8% 2,652,746 +71% 0.02% $292,178,898
PERCEPTIVE ADVISORS LLC 3.7% 2,586,295 +9% 4.5% $287,156,334
STATE STREET CORP 3.7% 2,573,529 +13% 0.01% $285,728,722
PRICE T ROWE ASSOCIATES INC /MD/ 3.7% 2,566,171 +55% 0.03% $284,923,000
WESTFIELD CAPITAL MANAGEMENT CO LP 3.2% 2,208,595 +14% 0.8% $245,220,303
GOLDMAN SACHS GROUP INC 3% 2,126,502 +8.2% 0.02% $236,105,516
FEDERATED HERMES, INC. 2.6% 1,785,716 +39% 0.29% $198,268,047
Polar Capital Holdings Plc 2.4% 1,663,632 +3% 0.52% $184,713,061
GEODE CAPITAL MANAGEMENT, LLC 2.2% 1,533,698 +8.3% 0.01% $170,320,392
Capital Research Global Investors 2.2% 1,532,303 +37% 0.02% $170,131,602
CITADEL ADVISORS LLC 1.8% 1,263,652 -11% 0.08% $140,303,282
Checkpoint Capital L.P. 1.7% 1,186,000 -3.4% 34% $131,681,580
Siren, L.L.C. 1.6% 1,136,275 +57% 2.6% $126,160,613
MORGAN STANLEY 1.6% 1,112,240 +58% 0.01% $123,492,178
FMR LLC 1.5% 1,025,840 -39% 0% $113,899,059
Pictet Asset Management Holding SA 1.4% 957,785 +44% 0.1% $106,252,095
Jupiter Topco LLC 1.3% 925,490 0% 0.04% $102,751,821
ALLIANCEBERNSTEIN L.P. 1.3% 894,723 -1.7% 0.03% $77,814,059
Woodline Partners LP 1.1% 758,891 0% 0.26% $84,259,668

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
36
Headline period
Q2 2026
Rows shown
1-25 of 36
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 620,818 $59,118,130 +$18,220,232 $95.22 56
2026 Q2 77,229,617 $8,550,536,847 +$437,344,841 $111.03 305
2026 Q1 73,450,451 $6,388,316,182 -$50,528,332 $86.97 284
2025 Q4 72,869,773 $7,800,510,442 +$220,704,819 $107.04 279
2025 Q3 70,886,984 $7,158,776,142 +$449,472,938 $100.99 263
2025 Q2 66,543,505 $4,204,958,379 +$136,584,141 $63.19 225
2025 Q1 64,595,384 $3,424,910,613 -$18,829,096 $52.97 226
2024 Q4 64,917,500 $3,634,217,578 -$158,677,402 $55.98 202
2024 Q3 67,700,036 $3,546,202,706 -$85,917,668 $52.39 175
2024 Q2 69,300,680 $2,846,175,742 +$52,795,226 $41.06 164
2024 Q1 68,030,458 $2,946,208,413 +$55,358,404 $43.33 166
2023 Q4 66,696,112 $3,065,811,725 -$41,849,707 $45.97 167
2023 Q3 68,143,293 $1,562,080,292 +$58,456,223 $22.92 143
2023 Q2 66,212,640 $1,092,127,229 +$94,106,398 $16.49 116
2023 Q1 60,335,883 $1,076,382,910 -$49,077,961 $17.84 125
2022 Q4 62,378,764 $1,816,485,551 +$85,568,575 $29.12 116
2022 Q3 59,549,165 $1,446,896,472 +$426,232,319 $24.50 99
2022 Q2 45,934,145 $190,627,988 -$18,795,957 $4.15 82
2022 Q1 48,841,709 $562,605,977 +$4,688,818 $11.52 105
2021 Q4 48,449,400 $483,522,595 -$537,879 $9.98 94
2021 Q3 47,950,622 $626,233,206 +$2,428,146 $13.06 93
2021 Q2 42,614,232 $834,516,313 -$3,429,160 $19.58 101
2021 Q1 47,577,014 $1,011,965,096 +$147,271,703 $21.27 119
2020 Q4 40,510,233 $1,201,291,923 +$39,479,834 $29.73 114
2020 Q3 39,249,591 $850,611,960 -$43,710,727 $21.67 114
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .